中国学者近期发表的论文
1.	Does an economic incentive affect provider behavior? Evidence from a field experiment on different payment mechanisms. Author: Xi X1, Wang E1, Lu Q1, Chen P1, Wo T1, Tang K1. Journal: J Med Econ. 2019 Jan;22(1):35-44. doi: 10.1080/13696998.2018.1539399. Epub 2018 Nov 15.    PubMed      DOI
2.	Constructing a value-based healthcare system for hypertensive patients through changing payment mode: evidence from a comparative study in rural China. Author: Miao Y1,2, Yuan X3, Gu J1, Zhang L4, He R4, Sandeep S4, Wu J5. Journal: J Med Econ. 2019 Mar;22(3):245-251. doi: 10.1080/13696998.2018.1558864. Epub 2019 Jan 17.    PubMed      DOI
3.	Real-world evidence of improved healthcare utilization in patients with schizophrenia or schizoaffective disorder after early treatment of paliperidone palmitate once-monthly treatment in Hong Kong. Author: Choon JWY1, Wu DBC1,2, Chong HY1, Lo WTL3, Chong CSY3, Chung WS4, Chui EMC5, Tomlinson B6, Lee VWY7, Lee SC6, Lee KKC1. Journal: J Med Econ. 2019 Mar;22(3):273-279. doi: 10.1080/13696998.2018.1560749. Epub 2019 Jan 14.    PubMed      DOI
4.	Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China. Author: Liao W1,2, Huang J1,2, Hutton D3, Li Q1,2. Journal: J Med Econ. 2019 Apr;22(4):344-349. doi: 10.1080/13696998.2019.1570221. Epub 2019 Feb 6.    PubMed      DOI
5.	Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. Author: Cai X1, Shi L2, Yang W1, Gu S3, Chen Y4, Nie L5, Ji L1. Journal: J Med Econ. 2019 Apr;22(4):336-343. doi: 10.1080/13696998.2019.1570220. Epub 2019 Feb 4.    PubMed      DOI
6.	Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China. Author: Zhao J1, Jiang K2, Li Q3, Zhang Y4, Cheng Y4, Lin Z5, Xuan J6. Journal: J Med Econ. 2019 May;22(5):439-446. doi: 10.1080/13696998.2019.1580714. Epub 2019 Mar 5.    PubMed      DOI
7.	Does the critical illness insurance reduce patients' financial burden and benefit the poor more: a comprehensive evaluation in rural area of China. Author: Jiang J1, Chen S2, Xin Y1, Wang X1, Zeng L1, Zhong Z1, Xiang L1. Journal: J Med Econ. 2019 May;22(5):455-463. doi: 10.1080/13696998.2019.1581620. Epub 2019 Mar 8.    PubMed      DOI
8.	Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China. Author: Liao M1, Jiang Q2, Hu H3, Han J1, She L1, Yao L1, Ding D1, Huang J1. Journal: J Med Econ. 2019 Feb 26:1-9. doi: 10.1080/13696998.2019.1588125. [Epub ahead of print]    PubMed      DOI
9.	Clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer in Chinese tertiary care hospital settings. Author: Qian Z1, Wang Y2,3, Tang Z4, Ren D2, Wang Z4, Chen W5,6, Li Z3,7. Journal: J Med Econ. 2019 Mar 27:1-8. doi: 10.1080/13696998.2019.1600524. [Epub ahead of print]    PubMed      DOI
10.	Influencing factors of disability among the elderly in China, 2003-2016: application of Bayesian quantile regression. Author: Xu X1,2, Chen L3,4. Journal: J Med Econ. 2019 Mar 26:1-7. doi: 10.1080/13696998.2019.1600525. [Epub ahead of print]    PubMed      DOI

同类著名期刊名称 h-index CiteScore European Journal of General Practice 23 1.46 Aerospace Medicine and Human Performance 62 0.69 JOURNAL OF FAMILY PRACTICE 89 0.25 Journal of Nepal Medical Association 16 0.20 Chronic Diseases and Injuries in Canada 0 0.00

中科院JCR同大类学科的热搜期刊 浏览次数 MEDICINE 299469 CANCER RESEARCH 165677 Molecular Medicine Reports 164445 International Journal of Nanomedicine 164235 CANCER LETTERS 159254 JOURNAL OF ETHNOPHARMACOLOGY 141428 BIOMEDICINE & PHARMACOTHERAPY 140257 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 135757 Theranostics 135687 International Journal of Environmental Research and Public Health 133397